Patients with chronic inducible urticaria see complete response to briquilimab at 6 weeks

Patients with chronic inducible urticaria experienced partial or complete response to briquilimab in 6 weeks with a favorable safety and tolerability profile, according to an online presentation by Jasper Therapeutics.
These patients have a “high unmet medical need,” Edwin Tucker, MD, MRCP, chief medical officer at Jasper Therapeutics, said during the presentation.
“Chronic inducible urticaria is a debilitating condition of the skin, and in severe subtypes, involves other organs, including the airway, which is going to be catastrophic for certain patients,” Tucker said.

Patients with chronic inducible urticaria experienced partial or complete response to briquilimab in 6 weeks with a favorable safety and tolerability profile, according to an online presentation by Jasper Therapeutics.
These patients have a “high unmet medical need,” Edwin Tucker, MD, MRCP, chief medical officer at Jasper Therapeutics, said during the presentation.
“Chronic inducible urticaria is a debilitating condition of the skin, and in severe subtypes, involves other organs, including the airway, which is going to be catastrophic for certain patients,” Tucker said.